AstraZeneca gets CDSCO nod for lung cancer drug
Lung cancer continues to pose a major public health challenge in India, ranking as the fourth leading cause of cancer-related deaths
Unlock Exclusive Insights with The Tribune Premium
Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits
Advertisement
AstraZeneca India Pharma on Thursday said it has received approval from the government authority for the import, sale, and distribution of a medication used in treating non-small cell lung cancer.
The company has received approval from the Central Drugs Standard Control Organisation (CDSCO), for Osimertinib tablets in strength of 40mg and 80mg, AstraZeneca India said in a statement.
Advertisement
The approval marks a critical step forward with Osimertinib as monotherapy in the treatment of patients with locally advanced, unresectable (Stage III) non-small cell lung cancer, it added.
This new indication represents a first-in-class treatment option in a setting for EGFR-mutated NSCLC post-chemoradiation, the drug firm stated.
"With Osimertinib's approval for this additional indication, we are reaching a significant milestone in redefining lung cancer treatment in India," AstraZeneca Pharma India Country President & MD Sanjeev Panchal said.
Advertisement
Lung cancer continues to pose a major public health challenge in India, ranking as the fourth leading cause of cancer-related deaths.
Advertisement
Advertisement